RiverVest Venture Partners Closes on Oversubscribed $184.4 Million Life Sciences Fund

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Life sciences venture capital firm RiverVest Venture Partners today announced the final closing of RiverVest Venture Fund IV, L.P., reaching $184.4 million in capital commitments in an oversubscribed fundraise. RiverVest Fund IV marks the firms fourth dedicated life sciences fund, bringing its total assets under management as of Sept. 30 to $753 million.

We are pleased that Fund IV exceeded our target, said RiverVest co-founder and managing director Jay Schmelter. It enables us to continue executing our strategy for generating top-quartile investor returns.

Schmelter credits RiverVests success to the firms focus on developing biopharma and medical device products that treat high, unmet medical needs, while attracting a buyer or being ready for an IPO within three to five years of the initial investment.

Since its initial closing late last year, RiverVest Venture Fund IV has invested in eight high potential companies, including founding or co-founding three, said RiverVest Managing Director John McKearn, Ph.D.

Earlier RiverVest Funds II and III have each provided net internal rates of return to their Limited Partners of over 20% per annum as of Sept. 30. That puts those funds performance in the top 5% of all venture funds started in the same respective vintage years according to Cambridge Associates U.S. Venture Capital Index, which benchmarks over 1,500 institutional-quality venture capital funds.

In addition to producing top investor returns, RiverVest portfolio companies have been the source of more than 25 approved medical products, including medical devices and drugs currently treating patients.

Since its founding, RiverVest has funded 47 and exited or taken public 22 innovative life science companies. A sample of RiverVest Fund II and Fund III exits and IPOs includes:

1) San Carlos-based Allakos, Inc. (NASDAQ:ALLK) (biopharma) completed initial public offering; 2) Cleveland-based Securus Medical Group, Inc. (medical device) sold to Boston Scientific Corporation; 3) Fort Worth-based ZS Pharma, Inc. (biopharma) completed initial public offering, then sold to a subsidiary of London-based AstraZeneca PLC; 4) San Diego-based Lumena Pharmaceuticals, Inc. (biopharma) sold to Dublin-based Shire plc; 5) Houston-based IDEV Technologies, Inc. (medical device) sold to Abbott Laboratories; and 6) Minneapolis-based Lutonix, Inc. (medical device) sold to C.R. Bard, Inc.

About RiverVest Venture Partners

RiverVest Venture Partners is a venture capital firm focused on identifying and shaping early stage life science companies to create significant shareholder value. With hands-on, high-level expertise and financial resources, RiverVest supports entrepreneurs by helping them achieve near-term objectives that position their companies for exit. Visit www.rivervest.com and follow us @Rivervest.

Callaway Zuccarello